MORRISVILLE, N.C. August 20, 2013 – Clinipace Worldwide, a global digital clinical research organization (dCRO), has announced the company has been named to Inc. Magazine’s 32nd annual Inc. 500 list for the fourth consecutive year. This prestigious list is a compilation of the fastest-growing privately held companies in the country, recognizing their success and potential for the future.

This is the fourth consecutive year that Clinipace Worldwide has been recognized—an honor bestowed to few other companies in the nation. The company was ranked 499th overall and generated a three-year growth rate of 918.55% from 2010 to 2012.

As a global full-service digital CRO, Clinipace Worldwide has pioneered an innovative service model to transform drug and medical device development that serves the unique needs of emerging, venture-backed and mid-tier life sciences firms.  With four global acquisitions over the past three years and 460 employees worldwide dedicated to developing and executing regulatory strategies, clinical development, and post-approval research, the company has managed over 1,200 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects.

“We’re honored by our fourth consecutive appearance on the Inc. list,” said Jeff Williams, CEO, Clinipace Worldwide. “We attribute this accomplishment to the dedication and innovation of our employees in serving clients, and we look forward to continue building a team that supports our therapeutic, operational, and global expansion goals while delivering innovative research services and technology to support growth within our industry.”

This year’s winners will be honored at the 32nd Annual Inc. 500|5000 Conference and Awards Ceremony October 10-12 at the Gaylord National in Washington D.C.

About Inc. 500|5000 List
In 1982, Inc. introduced the Inc. 500 list of the fastest-growing privately held companies in the United States. Since then, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success and the place where future household names first make their mark. In 2007, the Inc. 500 list expanded to the Inc. 500|5000, giving readers a deeper, richer understanding of the entrepreneurial landscape and capturing a broader spectrum of success. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. Inc. also ranks the fastest-growing companies by industry, metro area, revenue, and number of employees, and we also highlight women- and minority- run companies.

About Clinipace Worldwide
As a global full-service digital contract research organization (dCRO), we have pioneered an innovative technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms.  Powered by TEMPO™, our proprietary eClinical platform, our team of experts brings extensive therapeutic knowledge and insight into assisting life science firms in developing and executing regulatory strategies, clinical development, and post-approval research to ensure a successful drug and medical device development program.  We have managed over 1,200 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects in therapeutic areas such as cardiovascular & metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies).  Clinipace Worldwide is headquartered in Research Triangle Park, North Carolina with offices in Irvine (CA), Boulder (CO), Overland Park (KS), Zurich (CH), Munich (DE), High Wycombe (UK), Tel-Aviv (IL), Sao Paulo (BR), Buenos Aires (AR), Trivandrum Kerala (IN) and New Delhi (IN).  For more information, visit our website at www.clinipace.com.